Yifan Zhai Healthcare News

Follow[dot]Health is a news alert service for Heathcare and Healthtech. We are following 40K entities across 30M news items - with 1M items added monthly. This is selected healthcare news for Yifan Zhai, which is filed under People. There are 23 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
4/28/2022 ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting, Business News - AsiaOne
... McCormick Place; Chicago, IL ) on June 3–7, 2022. "This is the fifth consecutive year in which Ascentage-sponsored clinical results have been selected for presentations at the ASCO Annual Meeting," said Dr. Yifan Zhai , Chief Medical Officer. "We are pleased to be offered a further opportunity to showcase our ...
asiaone.com
4/28/2022 ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting | News | bakersfield.com
... McCormick Place; Chicago, IL) on June 3–7, 2022. "This is the fifth consecutive year in which Ascentage-sponsored clinical results have been selected for presentations at the ASCO Annual Meeting," said Dr. Yifan Zhai, Chief Medical Officer. "We are pleased to be offered a further opportunity to showcase our ...
bakersfield.com
4/27/2022 ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting
... McCormick Place; Chicago, IL ) on June 3–7, 2022. "This is the fifth consecutive year in which Ascentage-sponsored clinical results have been selected for presentations at the ASCO Annual Meeting," said Dr. Yifan Zhai , Chief Medical Officer. "We are pleased to be offered a further opportunity to showcase our ...
PR Newswire
4/14/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 | News | bakersfield.com bakersfield.com
4/14/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 | Business galvnews.com
4/14/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 Yahoo News
4/14/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 Yahoo News
4/14/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 onenewspage.com
4/13/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 PR Newswire
4/13/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 | Business & Finance | citizentribune.com citizentribune.com
3/11/2021 Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021 Business Insider
3/11/2021 Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021 Business Insider
5/15/2020 Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting PR Newswire
5/15/2020 Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting | Business & Finance | heraldchronicle.com PR Newswire
5/11/2020 Ascentage Pharma to Release Clinical Advances at 2020 ASCO Annual Meeting PR Newswire
5/10/2020 Ascentage Pharma to Release Clinical Advances at 2020 ASCO Annual Meeting | Business & Finance | manchestertimes.com PR Newswire
3/23/2020 Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States PR Newswire
5/22/2019 Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers | Business & Finance | heraldchronicle.com PR Newswire
5/22/2019 Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers PR Newswire